- Home
- GAME vs PMN Comparison
GAME vs PMN Comparison
Compare GAME & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- PMN
- Stock Information
- Founded
- GAME 2011
- PMN 2004
- Country
- GAME United States
- PMN Canada
- Employees
- GAME N/A
- PMN N/A
- Industry
- GAME
- PMN Pharmaceuticals and Biotechnology
- Sector
- GAME
- PMN Health Care
- Exchange
- GAME Nasdaq
- PMN Nasdaq
- Market Cap
- GAME 25.8M
- PMN 29.8M
- IPO Year
- GAME 2009
- PMN N/A
- Fundamental
- Price
- GAME $0.90
- PMN $0.82
- Analyst Decision
- GAME Strong Buy
- PMN
- Analyst Count
- GAME 3
- PMN 0
- Target Price
- GAME $3.67
- PMN N/A
- AVG Volume (30 Days)
- GAME 297.3K
- PMN 44.3K
- Earning Date
- GAME 04-15-2025
- PMN 03-31-2025
- Dividend Yield
- GAME N/A
- PMN N/A
- EPS Growth
- GAME N/A
- PMN N/A
- EPS
- GAME N/A
- PMN N/A
- Revenue
- GAME $99,072,646.00
- PMN N/A
- Revenue This Year
- GAME $102.01
- PMN N/A
- Revenue Next Year
- GAME $17.88
- PMN N/A
- P/E Ratio
- GAME N/A
- PMN N/A
- Revenue Growth
- GAME 210.51
- PMN N/A
- 52 Week Low
- GAME $0.65
- PMN $0.80
- 52 Week High
- GAME $2.25
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- GAME 54.66
- PMN 36.19
- Support Level
- GAME $0.84
- PMN $0.81
- Resistance Level
- GAME $0.95
- PMN $0.94
- Average True Range (ATR)
- GAME 0.06
- PMN 0.07
- MACD
- GAME 0.00
- PMN -0.01
- Stochastic Oscillator
- GAME 62.69
- PMN 6.07
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.